|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Pan-TRK IHC with Interpretation
Test Code12079
CPT Codes
88342<br><strong>This test is not available for New York patient testing</strong><br><strong>Restricted Client Code</strong>
Preferred Specimen
Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block
Other Acceptable Specimens
1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm
Instructions
1. Completed PhenoPath requisition form
2. Copy of pathology report(s) that corresponds to specimen(s)
3. Copy of any other relevant clinical data/reports (previous and presumptive diagnosis, pertinent medication/recent treatment, including dates of therapy)
4. Copy of current/previous flow cytometry and/or cytogenetics reports for hematopathology cases
5. Billing instructions and applicable information
6. Specimen(s) for testing/consultation
7. H&E of specimen to be tested, if possible or applicable
2. Copy of pathology report(s) that corresponds to specimen(s)
3. Copy of any other relevant clinical data/reports (previous and presumptive diagnosis, pertinent medication/recent treatment, including dates of therapy)
4. Copy of current/previous flow cytometry and/or cytogenetics reports for hematopathology cases
5. Billing instructions and applicable information
6. Specimen(s) for testing/consultation
7. H&E of specimen to be tested, if possible or applicable
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Methodology
Immunohistochemistry
Setup Schedule
Set up: Mon-Sat; Report available: 1-2 business days of receipt
Reference Range
See Laboratory Report
Clinical Significance
The Pan-TRK immunohistochemical assay detects expression of tropomyosin receptor kinase A, B, and C proteins arising from the NTRK 1, 2, and 3 genes, respectively. NTRK gene rearrangements occur in many different tumor types, often at low frequency, including lung non-small cell carcinomas (~1%), colorectal and other gastrointestinal related adenocarcinomas, breast carcinomas, melanoma, renal cell carcinomas, and adult brain tumors. Molecular testing (i.e., NGS or FISH) for an NTRK gene fusion is recommended for any equivocal or positive result by this assay to confirm the presence of an NTRK gene fusion. Patients having a tumor harboring an NTRK gene fusion may be responsive to NTRK inhibitor therapy.
(Ref: Cocco E, et al. Nat Rev Clin Oncol. 2018 December; 15(12): 731?747; Amatu A, et al. ESMO Open 2016;1:e000023)
(Ref: Cocco E, et al. Nat Rev Clin Oncol. 2018 December; 15(12): 731?747; Amatu A, et al. ESMO Open 2016;1:e000023)
